Regeneron Pharmaceuticals, Inc. (REGN)

$906.54

-0.78

(-0.09%)▲

Market is closed - opens 7 PM, 25 Apr 2024
star icon

Regeneron Pharmaceuticals Inc is a biopharmaceutical company that develops and commercializes medicines for serious medical conditions.

Insights on Regeneron Pharmaceuticals, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 3.15B → 3.43B (in $), with an average increase of 4.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, 817.8M → 1.15B (in $), with an average increase of 10.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 34.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 155.2%

Performance

  • $904.41
    $915.70
    $906.54
    downward going graph

    0.23%

    Downside

    Day's Volatility :1.23%

    Upside

    1.0%

    downward going graph
  • $684.81
    $998.33
    $906.54
    downward going graph

    24.46%

    Downside

    52 Weeks Volatility :31.4%

    Upside

    9.19%

    downward going graph

Returns

PeriodRegeneron Pharmaceuticals, Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-4.46%
1.7%
1.3%
6 Months
13.74%
11.3%
22.6%
1 Year
14.81%
5.4%
33.2%
3 Years
80.88%
13.9%
12.1%

Highlights

Market Capitalization
99.6B
Book Value
$242.47
Earnings Per Share (EPS)
34.73
PE Ratio
26.13
PEG Ratio
1.46
Wall Street Target Price
1048.72
Profit Margin
30.14%
Operating Margin TTM
29.2%
Return On Assets TTM
8.49%
Return On Equity TTM
16.26%
Revenue TTM
13.1B
Revenue Per Share TTM
122.94
Quarterly Revenue Growth YOY
0.6%
Gross Profit TTM
7.0B
EBITDA
4.7B
Diluted Eps TTM
34.73
Quarterly Earnings Growth YOY
-0.03
EPS Estimate Current Year
45.02
EPS Estimate Next Year
47.53
EPS Estimate Current Quarter
10.73
EPS Estimate Next Quarter
10.41

Analyst Recommendation

Buy
    75%Buy
    21%Hold
    3%Sell
Based on 33 Wall street analysts offering stock ratings for Regeneron Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
25
25
22
Hold
7
7
9
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 15.68%

Current $906.54
Target $1,048.72

Company Financials

FY18Y/Y Change
Revenue
6.7B
↑ 14.28%
Net Income
2.4B
↑ 103.95%
Net Profit Margin
36.42%
↑ 16.01%
FY19Y/Y Change
Revenue
7.9B
↑ 17.18%
Net Income
2.1B
↓ 13.44%
Net Profit Margin
26.91%
↓ 9.51%
FY20Y/Y Change
Revenue
8.5B
↑ 8.06%
Net Income
3.5B
↑ 66.05%
Net Profit Margin
41.35%
↑ 14.44%
FY21Y/Y Change
Revenue
16.1B
↑ 89.14%
Net Income
8.1B
↑ 129.86%
Net Profit Margin
50.25%
↑ 8.9%
FY22Y/Y Change
Revenue
12.2B
↓ 24.26%
Net Income
4.3B
↓ 46.28%
Net Profit Margin
35.64%
↓ 14.61%
FY23Y/Y Change
Revenue
13.1B
↑ 7.76%
Net Income
4.0B
↓ 8.87%
Net Profit Margin
30.14%
↓ 5.5%
Q3 FY22Q/Q Change
Revenue
2.9B
↑ 2.76%
Net Income
1.3B
↑ 54.41%
Net Profit Margin
44.81%
↑ 14.99%
Q4 FY22Q/Q Change
Revenue
3.4B
↑ 16.29%
Net Income
1.2B
↓ 9.01%
Net Profit Margin
35.06%
↓ 9.75%
Q1 FY23Q/Q Change
Revenue
3.2B
↓ 7.39%
Net Income
817.8M
↓ 31.68%
Net Profit Margin
25.86%
↓ 9.2%
Q2 FY23Q/Q Change
Revenue
3.2B
↓ 0.13%
Net Income
968.4M
↑ 18.42%
Net Profit Margin
30.66%
↑ 4.8%
Q3 FY23Q/Q Change
Revenue
3.4B
↑ 6.48%
Net Income
1.0B
↑ 4.07%
Net Profit Margin
29.97%
↓ 0.69%
Q4 FY23Q/Q Change
Revenue
3.4B
↑ 2.13%
Net Income
1.2B
↑ 15.06%
Net Profit Margin
33.77%
↑ 3.8%
FY18Y/Y Change
Total Assets
11.7B
↑ 33.89%
Total Liabilities
3.0B
↑ 13.62%
FY19Y/Y Change
Total Assets
14.8B
↑ 26.17%
Total Liabilities
3.7B
↑ 24.8%
FY20Y/Y Change
Total Assets
17.2B
↑ 15.93%
Total Liabilities
6.1B
↑ 65.2%
FY21Y/Y Change
Total Assets
25.4B
↑ 48.19%
Total Liabilities
6.7B
↑ 8.6%
FY22Y/Y Change
Total Assets
29.2B
↑ 14.86%
Total Liabilities
6.6B
↓ 1.73%
FY23Y/Y Change
Total Assets
33.1B
↑ 13.23%
Total Liabilities
7.1B
↑ 8.5%
Q3 FY22Q/Q Change
Total Assets
27.7B
↑ 1.73%
Total Liabilities
6.2B
↓ 4.28%
Q4 FY22Q/Q Change
Total Assets
29.2B
↑ 5.55%
Total Liabilities
6.6B
↑ 4.99%
Q1 FY23Q/Q Change
Total Assets
30.1B
↑ 2.89%
Total Liabilities
6.6B
↑ 0.22%
Q2 FY23Q/Q Change
Total Assets
30.7B
↑ 1.99%
Total Liabilities
6.6B
↑ 1.14%
Q3 FY23Q/Q Change
Total Assets
32.2B
↑ 4.91%
Total Liabilities
7.3B
↑ 9.33%
Q4 FY23Q/Q Change
Total Assets
33.1B
↑ 2.85%
Total Liabilities
7.1B
↓ 2.09%
FY18Y/Y Change
Operating Cash Flow
2.2B
↑ 67.94%
Investing Cash Flow
-1.5B
↑ 45.55%
Financing Cash Flow
-77.1M
↑ 215.98%
FY19Y/Y Change
Operating Cash Flow
2.4B
↑ 10.7%
Investing Cash Flow
-2.0B
↑ 38.61%
Financing Cash Flow
-252.1M
↑ 226.98%
FY20Y/Y Change
Operating Cash Flow
2.6B
↑ 7.74%
Investing Cash Flow
-70.6M
↓ 96.52%
Financing Cash Flow
-2.0B
↑ 681.63%
FY21Y/Y Change
Operating Cash Flow
7.1B
↑ 170.47%
Investing Cash Flow
-5.4B
↑ 7527.05%
Financing Cash Flow
-1.0B
↓ 48.96%
FY22Y/Y Change
Operating Cash Flow
5.0B
↓ 29.18%
Investing Cash Flow
-3.8B
↓ 29.72%
Financing Cash Flow
-1.0B
↑ 0.32%
Q3 FY22Q/Q Change
Operating Cash Flow
628.9M
↑ 11.43%
Investing Cash Flow
192.3M
↓ 146.46%
Financing Cash Flow
-725.0M
↑ 617.11%
Q4 FY22Q/Q Change
Operating Cash Flow
1.7B
↑ 173.48%
Investing Cash Flow
-1.9B
↓ 1066.04%
Financing Cash Flow
-247.6M
↓ 65.85%
Q1 FY23Q/Q Change
Operating Cash Flow
1.4B
↓ 20.48%
Investing Cash Flow
-235.7M
↓ 87.31%
Financing Cash Flow
-322.5M
↑ 30.25%
Q2 FY23Q/Q Change
Operating Cash Flow
1.0B
↓ 25.24%
Investing Cash Flow
-2.4B
↑ 912.69%
Financing Cash Flow
-614.2M
↑ 90.45%

Technicals Summary

Sell

Neutral

Buy

Regeneron Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • FMR Inc

    9.40%

  • Vanguard Group Inc

    8.05%

  • BlackRock Inc

    7.86%

  • JPMorgan Chase & Co

    6.58%

  • Capital World Investors

    4.67%

  • State Street Corporation

    4.47%

Company Information

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Organization
Regeneron Pharmaceuticals, Inc.
Employees
13450
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs